Key statistics
On Monday, PAVmed Inc (PAVM:NAQ) closed at 1.12, 86.70% above the 52 week low of 0.5999 set on Jun 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.14 |
---|---|
High | 1.14 |
Low | 1.09 |
Bid | 1.05 |
Offer | 1.33 |
Previous close | 1.11 |
Average volume | 26.73k |
---|---|
Shares outstanding | 10.41m |
Free float | 9.33m |
P/E (TTM) | -- |
Market cap | 11.55m USD |
EPS (TTM) | -8.17 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 21:00 GMT.
More ▼
- Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
- Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
- PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
- Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
- PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
- Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
- Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
- Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players
- American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test
More ▼